Study limitation: Level of evidence set to 2 reflecting a phase 1b/2a RCT, but the study was primarily powered for safety, not efficacy — exploratory efficacy findings should be interpreted with caution | ReachRx
Safety, pharmacokinetics, and exploratory efficacy of the oral ghrelin receptor agonist AC01 in heart failure with reduced ejection fraction (GOAL-HF1): a randomised, double-blind, placebo-controlled, phase 1b/2a study
Study limitation reported by the research below: “Level of evidence set to 2 reflecting a phase 1b/2a RCT, but the study was primarily powered for safety, not efficacy — exploratory efficacy findings should be interpreted with caution.”
